Fig. 7
From: Identification of comutation in signaling pathways to predict the clinical outcomes of immunotherapy
Combining SpHe-comut status with DDR-comut status and PD-L1 expression for the prediction of ICB therapy. A Kaplan–Meier survival curves of PFS comparing the patients within each of the three indicated subgroups classified by SpHe-comut status and DDR-comut status in the Rizvi cohort. B Comparison of proportion of patients with DCB calculated within each of the three indicated subgroups classified by SpHe-comut status and DDR-comut status in the Rizvi cohort. C Kaplan–Meier survival curves of PFS comparing the patients within each of the three indicated subgroups classified by SpHe-comut status and PD-L1 expression in the Rizvi cohort. D Comparison of proportion of patients with DCB calculated within each of the three indicated subgroups classified by SpHe-comut status and PD-L1 expression in the Rizvi cohort